



SIROLIMUS AND TACROLIMUS WITHOUT METHOTREXATE AS GRAFT-
VS.-HOST DISEASE PROPHYLAXIS AFTER MATCHED, RELATED PERIPH-
ERAL BLOOD STEM CELL TRANSPLANTATION: LOW TRANSPLANT RE-
LATED MORBIDITY AND EXCELLENT GVHD CONTROL
Cutler, C.1, Kim, H.T.2, Ho, V.1, Alyea, E.1, Lee, S.J.1, Fisher, D.C.1,
Hochberg, E.1, Miklos, D.1, Sonis, S.3, Soiffer, R.J.1, Antin, J.H.1 1.
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2. Bio-
statistical Science, Dana-Farber Cancer Institute, Boston, MA; 3. Oral
Medicine, Brigham and Women’s Hospital, Boston, MA
Sirolimus (Rapamycin, Rap) is a novel immunosuppressant sim-
ilar to tacrolimus (Tac), however, Rap inhibits T cell function via
FKBP12/mTOR and may also inhibit dendritic cell function. Rap
is synergistic with Tac and has no overlapping toxicity, allowing
their use in combination. We have shown that Rap, Tac and
low-dose methotrexate (Mtx) is effective GVHD prophylaxis after
URD transplantation. Since Mtx is associated with transplant tox-
icity and since MRD GVHD rates are lower than URD rates, we
hypothesized that Rap and Tac, without Mtx, would provide ef-
fective GVHD prophylaxis after MRD PBSCT while minimizing
transplant-related morbidity and mortality (TRM). Methods: 30
subjects underwent PBSCT from 6/6 HLA-matched siblings(29)
or parents(1) after Cy/TBI conditioning. GVHD prophylaxis con-
sisted of Rap (serum level 3-12 ng/ml) and Tac (serum level 5-10
ng/ml). Filgrastim (5 g/kg) was administered from d12 until
engraftment if needed. Results: The median age of subjects was 42
years (range 19-54). Diagnoses were AML(8), MDS(7), CML(7),
NHL(6), ALL(1) and ATLL(1). The median times to neutrophil
engraftment (500/l) and platelet engraftment (20,000/l and
100,000/l) were 14 (range 11-17), 13 (range 10-47), and 19
(range 11-189) days respectively. All patients survived to discharge,
at a median of 18 days from day 0 (range 15-54). Gr. II GVHD
occurred in 3 patients (10%), involved the skin (3) and gut (1), and
resolved with corticosteroids. No patient developed Gr. III-IV
GVHD or idiopathic pneumonia syndrome. 4 patients developed
thrombotic microangiopathy, but recovered normal renal function
when Tac was held. VOD occurred in 3 patients. 1 patient had
CMV reactivation and none had invasive fungal infections. Oral
mucositis was mild and as a result, 47% of patients required no
TPN. The median number of days of TPN use was 6. 9/28
evaluable patients developed chronic GVHD (3 extensive, 6 lim-
ited). 6 patients with advanced malignancies relapsed. 22/30 pa-
tients remain alive in complete remission. Causes of death include
relapse(6), VOD(1) and late pulmonary toxicity(1). The median
follow-up is 253 days (range 34-466). Relapse-free and overall
survival at day 100 are 93 and 97%, and at 1 year are 70 and 66%.
Conclusions: Rap and Tac without Mtx is effective for GVHD
prophylaxis after MRD PBSCT. Due to Mtx omission, mucositis
was reduced, engraftment was prompt and TRM was reduced. This
combination is worthy of broader study in allogeneic transplantation.
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS
(PTS) WITH THALASSEMIA MAJOR: AN INFERIOR OUTCOME WHEN
ANTITHYMOCYTE GLOBLINS (ATG) IS ADDED TO THE CONDITIONING
REGIMEN
Al-Jefri, A., Ayas, M., Al-Musa, A., Al-Mahr, M., Al-Fawaz, I.,
Saleh, M., Sabbah, R., Moussa, E., Khairy, A., El-Solh, H. King Faisal
Specialist Hospital & Research Center (KFSHRC), Riyadh, Saudi Arabia
Objectives: Allogeneic SCT is the only curative modality for pts
with Thalassemia Major. Busulfan (BU) and Cyclophosphamide (CY)
have traditionally been used as conditioning regimen with satisfactory
outcomes. ATG has been added by some investigators in heavily
transfused patients in an effort to reduce the risks of rejection. We
report here our SCT experience in Thalassemia pts showing an
inferior outcome in those who received ATG as part of the condi-
tioning regimen. Patients and Methods: From January 1998
through March 2001, 24 Thalassemia pts (11 class I, 11 class II, and
2 class III) underwent allogeneic SCT from HLA-matched related
donors at KFSHRC; median age was 4.5 years (range, 2-12.8 years),
conditioning was with BU 4 mg/kg/day p.o for 4 days, CY 50 mg/kg/
day i.v. for 4 days, and ATG 30 mg/kg/day i.v. for 4 days (group A).
Starting June 2001 through May 2003, ATG was removed from the
conditioning regimen; and 19 Thalassemia pts (12 class I, 5 class II,
and 2 class III) underwent matched related SCT with BU/CY only
(group B), median age was 4.5 years (range, 1.5-13.8 years). GVHD
prophylaxis was with Cyclosporin and MTX for both groups. Har-
vested marrow were not manipulated, median CD 34 dose was 8.8
106 (range, 2.3-17 106) and 8.6 106 (range, 4.9-14 106) per kg
of recipient body weight for groups A and B respectively. Engraftment
was assessed by VNTR or FISH on peripheral lymphocytes and/or
hemoglobin electrophoresis. Results: All pts had primary engraft-
ment; with a median time to ANC  0.5  109/L of 22 days (range,
14-29 days) and 18 days (range, 11-27 days) for the 2 groups respec-
tively, and a median time to self-sustaining platelet count of  20 
109/L of 18 days (range, 17-68 days) and 32.5 days (range, 16-68 days)
for the 2 groups respectively. Four pts in group A (16.6%) developed
severe acute GVHD (grade  3) of the skin, gut, and/or liver versus
only one patient in group B (5%). One patient in group A had chronic
GVHD versus 2 pts in group B. Secondary graft failure occurred in
ﬁve pts in group A and in none in group B. For group A, the 5 year
actuarial overall and event free survival was 86% and 65 % respec-
tively, and for group B, both the 2 year overall and event free survival
was 100%. Conclusions: Use of ATG in conditioning of Thalasse-
mia pts undergoing SCT is not beneﬁcial and appears to be associated
with a higher incidence of aGVHD and graft failure and with lower
survival.
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MARROW VERSUS PERIPHERAL BLOOD FOR GENO-IDENTICAL ALLO-
GENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOCYTIC LEU-
KAEMIA: INFLUENCE OF THE DOSE AND THE SOURCE OF STEM CELLS;
BETTER OUTCOME WITH RICH MARROW. ON BEHALF OF THE ACUTE LEUKAEMIA
WORKING PARTY (ALWP) OF THE EUROPEAN COOPERATIVE GROUP FOR BLOOD AND MARROW
TRANSPLANTATION (EBMT)
Gorin, N.C.1, Labopin, M.1, Rocha, V.2, Frassoni, F.3 1. Dept of
Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France,
Metropolitan; 2. Department of Hematology, Hopital Saint-Louis, Paris,
France, Metropolitan; 3. Department of Hematology, Ospedale San
Martino, Genova, Italy
Background: Several studies have compared bone marrow (BM)
and peripheral blood (PB) as stem cell sources in allografted patients,
but the cell doses infused have not been considered especially for
marrow. Material and methods: We studied retrospectively on the
ALWP/EBMT registry 881 adult patients with Acute Myelocytic
Leukaemia (AML), who received a non T depleted allogeneic BM
(n  515) or mobilised PB (n  366) standard transplant, in CR1,
from an HLA identical sibling, over a ﬁve year period from January
1994. Results: The BM cell dose ranged from 0.17 to 29  108/kg
with a median of 2.7 108/Kg. The PB cell dose ranged from 0.02 to
77  108/kg with a median of 9.3  108/kg.
Table. Major Differences in the Outcome of the 2 Groups
Group A Group B
Acute GVHD >3 Four One
Chronic GVHD One Two
Secondary graft failure Five None
Overall survival 86% 100%
Event free survival 65% 100%
9BB&MT
The median dose for patients receiving BM (2.7  108/Kg) gave
the greatest discrimination.
In multivariate analyses, high dose BM compared to PB, was asso-
ciated with lower TRM (RR  0.61 ; 95% CI 0.39-0.98; p  0.04),
better Leukemia Free Survival (RR  0.65; 95% CI 0.46-0.91; p 
0.013), and better Overall Survival (RR  0.64 ; 95% CI 0.44-0.92;
p  0.016). Conclusion: The present study in patients with AML
allografted in ﬁrst remission, indicates a better outcome with marrow
as compared to PB, when the dose of marrow infused is rich.
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LONG-TERM FOLLOW UP AFTER NON-MYELOABLATIVE ALLOGENEIC
STEM CELL TRANSPLANTATION FOR RENAL CELL CARCINOMA: THE
UNIVERSITY OF CHICAGO EXPERIENCE
Artz, A.S.1, van Besien, K.1, Zimmerman, T.1, Gajewski, T.F.1, Rini,
B.2, Hu, S.3, Stadler, W.M.1, Vogelzang, N.J.1 1. University of Chicago
Hospitals, Chicago, IL; 2. The University of California San Francisco,
San Francisco, CA; 3. St. John Mercy Medical Center, St. Louis, MO
Non-myeloablative hematopoietic allogeneic stem cell transplant
(NST) for metastatic renal cell carcinoma (RCC) has been dem-
onstrated to induce remissions in select patients (pts). However,
there are no long-term data on response duration, progression
after response, or overall survival. We report the long-term follow
up of NST for cytokine refractory metastatic RCC at the Univer-
sity of Chicago treated on a single protocol. Between 2/99 and
5/03, 18 pts underwent 19 matched-sibling peripheral harvested
NST’s after conditioning with ﬂudarabine and cyclophosphamide.
Post-transplant immunosuppression was with mycophenolate
mofetil until day 60 and tacrolimus tapering at day 90. Median age
was 55 years, performance status (PS) was 1 in 6/19 pts (PS  0 in
the remainder), and hemoglobin (Hb)  12 g/dL in 8/19 (42%).
There were 4 partial responses, but all have since progressed with
a median response duration of 609 days (range, 107-926). All
responders had chronic GVHD and were on immunosuppression
when progressive disease (PD) occurred. In 3 of 4 responders, PD
occurred at a site of prior response. Among all pts, DLI and/or
interferon were given to 3 pts for PD without response. Six pts died
early (ED) before day 120. Transplant related mortality was 4/6
among those with ED and 5/18 (28%) overall. Among those
without ED or response, 7/9 died from PD. All responders are
alive at a median of 1035 days (range 900-1405). The combination
of anemia and decreased PS was associated with adverse transplant
outcome (P  .035) and reduced survival (P  .004). Responders
had prolonged survival (P  .002) compared to non-responders. In
conclusion, NST for RCC as performed here leads to long term
but not durable partial responses and is associated with prolonged
survival in a minority of pts. Risk stratiﬁcation with simple clinical
factors such as anemia and PS  0 may reduce acute mortality and
enrich the population for potential responders, but further im-
provements in adoptive immunotherapy are necessary before NST
can be more generally applied for RCC.
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ALLOGENEIC TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
Bence-Bruckler, I.A.1, Bierman, P.J.5, Bociek, G.R.5, Stewart, D.A.3,
Gingrich, R.2, Vose, J.M.5, Bredeson, C.N.4, Rosenblum, M.4, Lynch,
J.C.5, Armitage, J.O.5 1. University of Ottawa, Ottawa, ON, Canada;
2. University of Iowa, Iowa City, IA; 3. University of Calgary, Calgary,
AB, Canada; 4. Medical College of Wisconsin, Milwaukee, WI; 5.
University of Nebraska Medical Center, Omaha, NE
The prognosis of mantle cell lymphoma (MCL) is poor with a
median survival of generally less than three years. In an attempt to
improve on the outcome of this disease, high dose therapy in the
form of both autologous and allogeneic stem cell transplantation
(SCT) has been explored. However, recurrences following autol-
ogous transplantation are common. Allogeneic SCT offers the
potential beneﬁts of an uncontaminated stem cells and a graft
versus lymphoma effect.
Thirty-seven patients with MCL underwent allogeneic SCT at
ﬁve institutions between 1994 and 2003. The median age at trans-
plant was 48 (range 34-59) years; 6 patients were female and 31
male. The median interval from diagnosis to transplant was 11
months (range 4-144 months). Seventy percent of patients had
received at least two prior chemotherapeutic regimens and 9% had
failed an autologous SCT. Donor source was matched related
donor (MRD) in 33 (89%) and matched unrelated donor (MUD)
in 4 (11%). Conditioning regimens varied by center; overall 26
patients (70%) received TBI-based conditioning. Donor source
was bone marrow in 14 (38%) and peripheral blood in 23 (62%).
Fourteen grafts (38%) were T-cell depleted and of these, 7 re-
ceived T-cell add-back. With a median follow-up for surviving
patients of 42 months (range 4-98 months), sixteen patients remain
alive post SCT. The cumulative incidence of non-relapse mortality
is 32% at day 100 and 41% at one year post transplant, with the
vast majority of deaths occurring by one year post transplant.
Thirty four of 37 patients were evaluable for acute graft-versus-
host disease (GVHD). The cumulative incidence of acute GVHD
was 62% at 100 days. Of 20 patients evaluable for extensive chronic
GVHD, the cumulative incidence was 30% at one year. Three year
estimates of event-free and overall survival are 39% (95% CI
23%-55%) and 45% (95% CI 28%-61%) respectively. Progressive
disease has been documented in six patients. This data demon-
strates that allogeneic SCT in MCL can result in prolonged disease
control in selected, pretreated patients, although nonrelapse mor-
tality remains a signiﬁcant problem with this approach.
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DISSECTION OF AN MHC MISMATCHED ALLOGENEIC TRANSPLANT
MODEL DURING DONOR CD4CD25 T-CELL FACILITATION OF HE-
MATOPOIETIC PROGENITORS
Hanash, A.M., Levy, R.B. University of Miami School of Medicine,
Miami, FL
Identifying cell populations capable of supporting allogeneic he-
matopoietic stem/progenitor cell engraftment without inducing
GVHD could lead to more potential hematopoietic cell transplant
(HCT) recipients and broaden the acceptable donor pool. We have
examined the effect of CD4CD25 regulatory (T-reg) cells on
engraftment in a sublethal (7.0 Gy TBI) MHC mismatched model
by transplanting donor C57BL/6 (B6) T-regs and T-cell depleted
bone marrow (BM-TCD) into BALB/c recipients and observed
long-term chimerism (p  .05) and diminished rejection (p  .05).
This non-GVHD inducing T-cell population was also associated
with signiﬁcantly greater splenic lineage committed (GM, p 
.001) and multi-potential (HPP, p  .05) donor progenitor colo-
nies 7 days post-BMT. To dissect the allogeneic transplant com-
ponents involved in this progenitor support, splenic day 7 donor
GM progenitors were assessed following transplants eliminating
donor T-regs’ allo-recognition in the recipient and transplants
selectively neutralizing populations in the recipient capable of
allogeneic rejection. T-regs from BALB/c  B6 F1 mice signiﬁ-
cantly increased donor B6 colonies whether transplanted into re-
cipients lacking (BALB/c, H-2d, p  .001) or possessing (BALB.K,
H-2k, p  .05) MHC that was allogeneic to the donor T-regs.
Importantly, when eliminating the recipients’ T-cell resistance by















N  4 N  9 N  6 N  19 N  18
Pretreatment
PD at transplant 2 (50) 5 (83) 5 (56) 0.57 .37
Hb < 12 g/dL 1 (25) 3 (33) 4 (67) .48 .06
PS > 0 0 2 (22) 4 (67) .06 <.01
Hb < 12 g/dL and/or
PS > 0 1 (25) 4 (44) 6 (100) .04 <.01
GVHD
aGVHD > 1 0 1 (11) 2/5 (40) .23 .03
cGVHD, ext 4 (100) 3 (33) n/a .76
Nineteen transplants performed with 18 patients. “Other” includes patients who did not
respond or suffer early death. Across group comparison uses a two-tailed Fisher’s
exact test for a 3  2 table. Survival analysis is for 18 patients. P value derived from
univariate log-rank test for each variable.
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